Blockchain

Multipool Secures Strategic Investment from Industry Giant Kronos Research

on

    More in Blockchain:

    Majuro, Marshall Islands, July 23rd, 2024, Chainwire

     

    Multipool, a leading innovator in the blockchain and cryptocurrency industry, today announces a strategic investment from Kronos Research. This investment solidifies Kronos’s stance of on-chain order books being the future of the industry and marks a significant milestone in strategic cooperation between the two companies and their commitment to decentralized finance.

    “We’re absolutely thrilled to be working with Kronos Research, with our expertise in the DeFi sector and the potential of our fully trustless decentralized on-chain orderbook, we envision an eventful future working with some of the best and brightest in the industry at Kronos Research.” Steve Murray, Core Contributor at Multipool.

    “At Kronos, we have been leading the charge in liquidity provision, driven by our belief in trustless transactions and their transformative potential. We are thrilled to partner with Multipool to advance the digital asset landscape, providing enhanced solutions for global traders and investors.” Vincent Liu, COO of Kronos Research

    The Future of Decentralized Finance

    Multipool’s aim of delivering a fully on-chain trustless orderbook to the DeFi industry aligns with Kronos’s vision of democratizing access to compliant advanced financial tools. This marks the first step in a long and fruitful partnership that will bring stability, awareness and access to a suite of full decentralized tools currently in high demand industry wide.

    To learn more about Multipool and its features, users can visit:

    Website – www.multipool.finance

    Telegram – t.me/multipoolfi

    X – https://x.com/multipoolfi

    CMC-Community – https://coinmarketcap.com/community/profile/multipool/

    About Multipool

    Multipool is a cutting-edge decentralized exchange (DEX) transforming the trading landscape for real-world assets (RWAs) and cryptocurrencies. Multipool is designed for fairness and equality, featuring a fully decentralized on-chain order book, deep liquidity through dynamic bracket pools, and seamless trading of RWAs and cryptocurrencies. Utilizing world-class innovations including industry-first FIX APIs, low latency networks, zero price impact auctions, trustless RFQs, peer-to-peer repo lending, and MEV bot protection, Multipool sets a new standard in DeFi trading. Experience unparalleled efficiency and security in the user’s trading journey with Multipool – The DEX with CEX appeal.

    Website: https://www.multipool.finance/

    About Kronos Research

    Kronos Research is a technology and data-driven trading firm transforming the digital asset landscape by cultivating a dynamic financial ecosystem with exceptional trading performance, advanced cryptocurrency investment strategies, and extensive liquidity provision capabilities.

    Their advanced machine-learning techniques and state-of-the-art trading infrastructure form the backbone of our quantitative trading operations. These enables them to deliver precise data and insights, bolster risk management, develop effective trading strategies, and empower informed investment decisions.

    By leveraging our expertise, they strive to foster strong partnerships and deliver significant value through continuous advancement and innovation.

    For further information or media inquiries, users can contact:

    Marketing Department

    [email protected]

    Website: www.kronosresearch.com

    Social Media: [LinkedIn] [Twitter] [Facebook] [Instagram]

     

    Contact

    Public Relations Manager
    Angie Hermosa
    Multipool
    [email protected]

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

    2024-10-02T11:08:00Z

    PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

    Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

    Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

    • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
    • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
    • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

    Keiretsu Forum: A Global Leader in Early-Stage Innovation

    Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

    Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

    "Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

    Event Details

    • Date: October 31, 2024
    • Time: 8:00 AM – 6:00 PM EDT
    • Location: Convene City View, 30 S 17th St, Philadelphia, PA

    Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

    About Keiretsu Forum :

    Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

    The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

    About Dr. Martin Gershon

    Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

    Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

    For media inquiries, please contact:

    Cindi Sutera
    AMS Communications
    [email protected]
    610-613-2773


    GlobeNewsWire News

    Recent Comments